Aurobindo Pharma Q1FY27 Revenue Up 16.3% to ₹9,150 Cr; Net Profit Rises 25.2% to ₹1,032 Cr
Aurobindo Pharma reported Q1FY27 consolidated revenue of ₹9,150 crore, up 16.3% YoY. Net profit rose 25.2% to ₹1,032 crore. US revenue grew 8.1% to ₹3,770 crore, Europe revenue increased 25.6% to ₹2,937 crore. The company received USFDA approval for 10 products and generated USD 98 million in free cash flow. An earnings call is scheduled for August 6, 2026.
The announcement includes significant financial performance metrics (revenue and profit growth), key operational achievements (USFDA approvals), and strategic financial management (cash flow, acquisition payments, buyback), which are material to investors.
The company reported strong year-on-year growth in revenue and net profit, along with positive commentary from the management and approvals from the USFDA.
Aurobindo Pharma Limited announced its consolidated financial results for the first quarter ended June 30, 2026. The company reported a 16.3% year-on-year increase in Revenue from Operations to ₹9,150 crore, up from ₹7,868 crore in Q1FY26. Net Profit for the quarter surged by 25.2% to ₹1,032 crore, compared to ₹824 crore in the same period last year.
Revenue from operations saw a 3.4% sequential increase from ₹8,853 crore in Q4FY26. EBITDA before R&D increased by 13.4% YoY to ₹2,208 crore, with an EBITDA margin of 24.1% before R&D. EBITDA (before forex and exceptional items) grew by 20.0% YoY to ₹1,924 crore, resulting in an improved EBITDA margin of 21.0% from 20.4% in Q1FY26.
The company's performance was driven by growth across its businesses. US revenue increased by 8.1% YoY to ₹3,770 crore (USD 399 million), Europe revenue grew by 25.6% YoY to ₹2,937 crore (EUR 267 million), and Growth Markets revenue saw a substantial increase of 37.7% YoY to ₹1,063 crore (USD 113 million). The ARV business revenue stood at ₹330 crore (USD 35 million).
Aurobindo Pharma received final approval for 10 products from the USFDA during the quarter. The company also maintained a strong net cash position of USD 42 million as of June 30, 2026, after accounting for the Lannett acquisition and a share buyback. Free cash flow generated during the quarter was USD 98 million. Basic and Diluted EPS stood at ₹17.86 per share.
Commenting on the performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director, stated, "We have commenced FY27 on a strong note, delivering healthy growth across our businesses through disciplined execution, operational excellence, and the continued strength of our diversified product portfolio."
The company will host an earnings call on August 6, 2026, at 8:30 AM IST to discuss its performance.
What to do with a filing like this
Aurobindo Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aurobindo Pharma Limited. Read the original for the full detail.